Benitec Biopharma (Benitec Biopharma) Total Current Assets : $14.37 Mil (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Benitec Biopharma Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Benitec Biopharma's total current assets for the quarter that ended in Mar. 2024 was $14.37 Mil.

Benitec Biopharma Total Current Assets Historical Data

The historical data trend for Benitec Biopharma's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma Total Current Assets Chart

Benitec Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Current Assets

Get a 7-Day Free Trial

18.76

10.81

20.61

4.82

3.73

Benitec Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															7.40	3.73	26.41	20.80	14.37

Benitec Biopharma Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Benitec Biopharma's Total Current Assets for the fiscal year that ended in Jun. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	2.477	+	0.055	+	0	+	1.197
	=	3.73

Benitec Biopharma's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	14.143	+	0.053	+	0	+	0.17
	=	14.37

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Benitec Biopharma (NAS:BNTC) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Benitec Biopharma's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	14.143	-	3.499	+	0.75 * 0.053	+	0.5 * 0
=	10.68

Benitec Biopharma Total Current Assets Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Benitec Biopharma (Benitec Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (NAS:BNTC) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

3940 Trust Way, Hayward, CA, USA, 94545

Website

https://www.benitec.com

Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.

Executives

J Kevin Buchi	director	41 MOORES ROAD, FRAZER PA 19355
Megan Boston	director, officer: Executive Director	LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Steven Michael Oliveira	10 percent owner	18 FIELDSTONE COURT, NEW CITY NY 10956
Patrick Soon-shiong	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Edward F Smith	director	C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104
California Capital Equity, Llc	10 percent owner	10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Peter Francis	director	LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Jerel A. Banks	director, officer: Chief Executive Officer	LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000